Matthew Dumont

Matthew Dumont is an experienced leader in business development and corporate strategy within the pharmaceutical and medical device industries. Currently serving as the Head of Urology New Business Development at Boston Scientific, Matthew is responsible for driving strategic acquisitions and investments for a $2B+ urology business unit, with a focus on expanding offerings in stone management, prostate health, and men’s health. Prior to this role, Matthew held the position of Executive Director at Veloxis Pharmaceuticals, where major achievements included leading a $1.3B acquisition focused on transplant immunotherapies. Matthew's earlier experience encompasses managing global business development at Viatris, closing transactions worth over $11 billion, and contributing to corporate development at Catalent, including significant deals and IPO activities. Educational qualifications include an MS/BS in Chemical and Biomolecular Engineering from The Johns Hopkins University and an MBA from Columbia Business School.